藤江成光さん、先週の私の質疑のその後を厚労大臣に質してくれました。

Summary

In this video, Kazuo Haraguchi, a member of the House of Representatives, addresses concerns regarding the safety of the replicon COVID-19 vaccine produced by Meiji Seika Pharma. He questions the lack of thorough clinical trials and the unexplained deaths linked to the vaccine, emphasizing issues with transparency and government accountability. Haraguchi highlights the discrepancies in official reports, including unexplained deaths and challenges in determining the vaccine’s causal relationship with these fatalities. The discussion also touches on broader issues of COVID-19 data manipulation and vaccine safety, underscoring the need for more rigorous investigation and transparency.

Takeaways

• 😀 The speaker, Kazuo Haraguchi, is a member of the House of Representatives, addressing the audience early in the morning, acknowledging the viewers on multiple platforms including YouTube and Nico Live.
• 😀 Haraguchi emphasizes his involvement in political efforts, recognizing the National Federation of Democratic Party of Japan's influence on local elections and the growing strength of local assembly members.
• 😀 During a press conference, Haraguchi discusses questions related to the investigation of deaths following COVID-19 vaccinations, with a focus on the replicon vaccine.
• 😀 Haraguchi highlights concerns over the lack of available information, particularly the unknown death dates of two reported deaths after receiving the replicon vaccine.
• 😀 Minister Fukuoka responds, stating that further investigation is ongoing, but acknowledges that most deaths cannot be linked directly to the vaccine due to insufficient data.
• 😀 Haraguchi asks for clarity on the Ministry's efforts to gather missing data and reassess causal relationships regarding vaccine-related deaths, given that 99.4% of deaths cannot be evaluated due to lack of information.
• 😀 Acknowledging that investigations have been carried out, Haraguchi questions the thoroughness and effectiveness of the assessments, especially regarding reports of adverse events and the vaccine's safety profile.
• 😀 Haraguchi raises concerns about the potential risks of the replicon vaccine, comparing it to other vaccines like Pfizer and Moderna, particularly its self-replicating nature which could potentially cause side effects that are difficult to control.
• 😀 He criticizes Meiji Seika Pharma for rushing the approval and sale of the replicon vaccine without sufficient long-term clinical trials and safety data, arguing that this could put public health at risk.
• 😀 The script ends with a focus on discrepancies in data reporting, particularly the misattribution of deaths to COVID-19, and Haraguchi's concerns about misinformation being spread regarding vaccine safety and effectiveness.

Q & A

What issue was raised by Representative Kazuo Haraguchi regarding the COVID-19 vaccine deaths?

Representative Kazuo Haraguchi raised concerns about the deaths following the COVID-19 vaccine, particularly the lack of clarity around the dates of death for two of the reported cases. He questioned the ongoing investigation and the transparency of the data related to vaccine deaths.

What did Minister Fukuoka say about the investigation into the vaccine deaths?

Minister Fukuoka acknowledged the investigation but mentioned that it was difficult to assess the causal relationship in many cases due to a lack of sufficient information. He stated that the investigation would continue, and additional reports were being made to the PMDA (Pharmaceuticals and Medical Devices Agency).

What concerns did Representative Haraguchi have about the difficulty in assessing the causal relationship with the vaccine?

Haraguchi expressed concern that 99.4% of the reported deaths could not be assessed for a causal relationship due to insufficient data, and he questioned whether efforts were being made to gather missing information to reassess these cases.

What was the response to Haraguchi’s concerns about the high number of unassessed deaths?

Minister Fukuoka responded by saying that although additional reports were made to the PMDA, there were still many cases where it was challenging to determine the cause, such as deaths caused by complications or concomitant use of other medications.

What did Haraguchi imply about the replicon vaccine produced by Meiji Seika Pharma?

Haraguchi implied that the replicon vaccine produced by Meiji Seika Pharma was rushed to market without sufficient clinical trials, which he compared to allowing people to drive with a provisional license. He was concerned about its safety and the lack of long-term clinical data.

What is the key concern about the replicon vaccine, as raised by Dr. Haraguchi?

Haraguchi’s key concern about the replicon vaccine was that it self-replicates within the body, which could potentially cause prolonged side effects. He questioned the safety of such a new drug, especially since it had not undergone long-term trials to ensure its safety.

How did Haraguchi criticize the legal aspects of the lawsuit filed by Meiji Seika Pharma against him?

Haraguchi criticized the lawsuit filed by Meiji Seika Pharma, calling it problematic, especially in light of the lack of sufficient clinical trials for the replicon vaccine. He suggested that the lawsuit might be politically motivated, possibly in an attempt to influence elections.

What did Haraguchi point out about the number of clinical trials for the replicon vaccine?

Haraguchi pointed out that the clinical trials for the replicon vaccine were insufficient, noting that only about 18,000 people had been involved in the trials, with much of the data coming from Vietnam. He questioned how such limited trials could reliably confirm the vaccine's safety and efficacy.

What discrepancy did Haraguchi observe in the reporting of deaths during the COVID-19 pandemic?

Haraguchi observed that there were discrepancies in the reporting of deaths, particularly with the categorization of deaths as COVID-related. He pointed out that pneumonia-related deaths may have been misattributed to COVID-19, especially in the elderly, affecting the overall death statistics.

What did Haraguchi suggest about the government's handling of death data related to COVID-19?

Haraguchi suggested that the Japanese government was inflating the number of COVID-19 deaths for political reasons. He criticized the practice of labeling deaths from other causes, such as traffic accidents, as COVID-related deaths after testing for the virus in hospitals, arguing that this misrepresented the actual impact of the virus.